Physician profile
Avi Retter
NPI 1205894268
$7,058.21
in general payments reported to CMS, 2019-2025
36 companies · $36.90 in 2025
The $36.90 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $2,194 · 2021: $604 · 2023: $1,443 · 2024: $2,230 · 2025: $36.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,398 · Food and Beverage: $312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,397.50 |
| Food and Beverage | $312.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,749.35 | 2019-2024 | Talvey, Tecvayli |
| Karyopharm Therapeutics INC. | $1,875.00 | 2020 | |
| Puma Biotechnology, INC. | $146.89 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.77 | 2019-2024 | Alunbrig, Ninlaro |
| Amgen INC. | $84.51 | 2019-2020 | |
| Kite Pharma, INC. | $73.74 | 2020-2021 | |
| Pfizer INC. | $71.02 | 2019-2025 | |
| Lilly USA, LLC | $70.28 | 2019-2020 | |
| Daiichi Sankyo INC. | $67.25 | 2023 | Injectafer |
| Secura Bio, INC. | $65.02 | 2019-2021 | |
| Astellas Pharma US INC | $60.17 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.87 | 2019-2021 | |
| Emd Serono, INC. | $50.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $49.84 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $49.41 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $37.82 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $37.70 | 2019-2020 | |
| Array Biopharma INC | $37.50 | 2019 | |
| Merck Sharp & Dohme LLC | $31.82 | 2019-2025 | Keytruda, Welireg |
| Eisai INC. | $30.11 | 2021 | |
| Stemline Therapeutics INC. | $29.76 | 2020 | |
| Epizyme, INC. | $29.50 | 2021 | |
| Gilead Sciences, INC. | $24.34 | 2019-2021 | |
| Advanced Accelerator Applications | $23.79 | 2019 | |
| Celgene Corporation | $23.57 | 2021 | |
| Dova Pharmaceuticals | $21.82 | 2020 | |
| Genzyme Corporation | $20.11 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $18.64 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.36 | 2020 | |
| Foundation Medicine, INC. | $18.33 | 2021 | |
| Sanofi-Aventis U.S. LLC | $18.25 | 2021 | |
| Alnylam Pharmaceuticals INC. | $16.54 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $15.61 | 2020 | |
| Myovant Sciences INC. | $15.51 | 2021 | |
| Genentech USA, INC. | $11.73 | 2019 | |
| Incyte Corporation | $11.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avi Retter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.